Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...
Researchers at Boston University’s Structural Bioinformatics Lab are working with Mercury Computer Systems to develop a system that will make it easier for pharmaceutical companies to develop new ...
More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...
On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...
Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
Whether a smartphone battery lasts longer or a new drug can be developed to treat incurable diseases depends on how stably the atoms constituting the material are bonded. The core of 'molecular design ...
13don MSN
The rise of ‘agonorexia’: People are developing brand new eating disorders on GLP-1 agonist drugs
Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results